Floatz logo

Fexagratinib

Recurrent Malignant Solid Neoplasm

National Cancer Institute (NCI)Small moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
81/ 100

Competitive context

75 Active assets in the Recurrent Malignant Solid Neoplasm cohort.

Asset / SponsorPhaseRating
Cediranib
National Cancer Institute (NCI)
Phase 2BB
Crizotinib
M.D. Anderson Cancer Center
Phase 2B
Nivolumab
National Cancer Institute (NCI)
Phase 2B
Pembrolizumab
University of California, Davis
Phase 2B
Epirubicin
University of California, Davis
Phase 2B

View all 50 →

Same molecule, other indications

Fexagratinib is also rated in:

squamous cell lung carcinomaDormant
BB
Indicative ·
64 / 100
View asset →
non-small cell lung carcinomaDormant
B
Indicative ·
59 / 100
View asset →
adenocarcinomaDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →